Diabetes
Conference Coverage
Debate: Initial combination therapy for type 2 diabetes?
Ralph A. DeFronzo, MD, argued for combination therapy at the time of diagnosis, and David M. Nathan, MD, countered that sequential therapy is a...
News
Spirometry predicts mortality in type 2 diabetes
PRISm occurs in approximately 10% of the general population and has been identified as a predictor of adverse health outcomes.
News
Evidence weighed for suicide/self-harm with obesity drugs
“It is not yet clear whether the reported cases are linked to the medicines themselves or to the patients’ underlying conditions or other factors...
News
Link between low co-pays for new diabetes drugs and patient adherence
Low co-pays linked with substantially better 12-month adherence to expensive SGLT2 inhibitors and GLP-1 agonists in U.S. patients with type 2...
News
FDA approves cognitive-behavioral app for adults with type 2 diabetes
The app will be available to patients exclusively by prescription, with a planned 90-day use duration.
Conference Coverage
Aging and type 1 diabetes: ‘Complete picture’ 40 years on
“The EDIC study is now shifting its focus during the next 5 years to understand the clinical course of type 1 diabetes in the setting of advancing...
News
Treating obesity: Will new drugs end the crisis?
The drugs offer new hope to millions with obesity complications. But to truly turn the tide on our 42% obesity rate, much more work remains to be...
News
GLP-1 agonists offer multiple benefits in type 2 diabetes with liver cirrhosis
“GLP-1 RAs may be a treatment option for diabetes patients with liver cirrhosis,” but additional studies are needed to confirm the results, the...
Conference Coverage
Education before Ramadan key to safe fasting with diabetes
“With correct advice and support” from knowledgeable health care professionals “most people with type 2 diabetes can fast safely during Ramadan...
Conference Coverage
COORDINATE-Diabetes: A ‘wake-up call’ for many specialties
“I look at COORDINATE as a wake-up call to the need for multispecialty approaches to people with type 2 diabetes and cardiovascular disease.”